Role of Maintenance Therapy in Ovarian Cancer

Video

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
Related Content
Exercise May Mitigate Chemo-Induced Peripheral Neuropathy in Ovarian Cancer | Image Credit: © Lars Neumann - stock.adobe.com.

Exercise May Mitigate Chemo-Induced Peripheral Neuropathy in Ovarian Cancer

December 5th 2023
Article

Implementing exercise programs into standard oncology care may help improve quality of life for patients with ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Results from phase 1 of the RAMP 201 study shows efficacy in treating patients with recurrent low-grade serous ovarian cancer with avutometinib plus defactinib, regardless of previous treatment.

Avutometinib/Defactinib Shows Efficacy in Treating Low-grade Serous Ovarian Cancer

November 7th 2023
Article

Results from phase 1 of the RAMP 201 study shows efficacy in treating patients with recurrent low-grade serous ovarian cancer with avutometinib plus defactinib, regardless of previous treatment.

Population Testing to Prevent Gynecologic Cancers

Population Testing to Prevent Gynecologic Cancers

September 12th 2018
Podcast

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Collaboration among surgical specialties allows for safe removal of all visible tumors, thus improving survival in patients with advanced ovarian cancer, says Donal J. Brennan, MB, PhD.

Multidisciplinary Surgery May Improve Survival in Advanced Ovarian Cancer

November 1st 2023
Article

Collaboration among surgical specialties allows for safe removal of all visible tumors, thus improving survival in patients with advanced ovarian cancer, says Donal J. Brennan, MB, PhD.

Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α–positive, platinum-resistant ovarian cancer, experts say.

Mirvetuximab Soravtansine Improves Survival VS Chemo in FRα+ Ovarian Cancer

October 31st 2023
Article

Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α–positive, platinum-resistant ovarian cancer, experts say.